Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) EBT: 2009-2025

Historic EBT for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to -$1.1 million.

  • Lifecore Biomedical's EBT rose 84.40% to -$1.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$38.7 million, marking a year-over-year decrease of 506.50%. This contributed to the annual value of -$38.7 million for FY2025, which is 506.50% down from last year.
  • Per Lifecore Biomedical's latest filing, its EBT stood at -$1.1 million for Q2 2025, which was up 92.46% from -$14.8 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's EBT ranged from a high of $15.0 million in Q1 2024 and a low of -$36.8 million during Q2 2023.
  • For the 3-year period, Lifecore Biomedical's EBT averaged around -$7.7 million, with its median value being -$9.2 million (2023).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 1,285.65% in 2021, then surged by 254.15% in 2023.
  • Lifecore Biomedical's EBT (Quarterly) stood at $1.3 million in 2021, then tumbled by 823.03% to -$9.2 million in 2022, then soared by 254.15% to $14.2 million in 2023, then plummeted by 146.05% to -$6.5 million in 2024, then soared by 84.40% to -$1.1 million in 2025.
  • Its EBT was -$1.1 million in Q2 2025, compared to -$14.8 million in Q1 2025 and -$6.5 million in Q4 2024.